Small-cell lung cancer

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

SCLC commonly presents as a central mass with bulky nodal disease and early metastatic spread. Although pathological diagnosis is essential, the pathway should be faster than a generic sequential work-up: contrast CT maps an accessible target, bronchoscopy or EBUS can provide tissue and nodal information, and brain imaging identifies common occult metastases. A severe paraneoplastic or compressive complication may require urgent management before every staging detail is complete. The patient should meet the thoracic oncology team promptly because clinical condition can change over days rather than months.

Systemic treatment is central even in apparently confined SCLC because micrometastatic disease is likely. Limited-stage treatment aims for cure in suitable patients by combining platinum-etoposide with thoracic radiotherapy, ideally without avoidable delay. Extensive-stage therapy is disease-controlling; NICE supports atezolizumab with carboplatin and etoposide for people meeting its appraisal criteria. Response can be dramatic but surveillance must anticipate relapse and treatment toxicity. Brain management requires individual discussion of MRI findings, thoracic response, prophylactic cranial irradiation, cognition and current national guidance instead of an automatic assumption that all patients receive the same cranial strategy.

Key points

Small-cell lung cancer is a high-grade neuroendocrine malignancy with early dissemination, rapid doubling and initial treatment sensitivity followed by a substantial risk of relapse.
Obtain pathological confirmation promptly, but design one efficient diagnostic and staging sequence because serial low-yield procedures can consume a clinically important treatment window.
Use TNM staging and also describe limited-stage disease when it can be encompassed within a tolerable radical radiotherapy field; extensive-stage disease exceeds that practical boundary.
Baseline staging generally includes contrast CT, brain imaging and, when radical treatment is contemplated, PET-CT or other tests that resolve curative-field uncertainty.
Fit limited-stage disease is usually treated with platinum-etoposide and early concurrent thoracic radiotherapy; timing and agent choice require specialist assessment of toxicity and treatment volume.
Eligible untreated extensive-stage disease may receive atezolizumab with carboplatin and etoposide under NICE TA638, followed by maintenance atezolizumab according to the licensed pathway.
Hyponatraemia, ectopic ACTH effects, Lambert-Eaton syndrome, superior vena cava obstruction, brain metastases and spinal cord compression can be the presenting clinical problem.
At relapse, the previous response duration, performance status, organ function, disease distribution and current NICE options determine whether to rechallenge, change systemic treatment, use radiotherapy or focus on symptoms.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Tobacco smoke

Small-cell lung cancer is strongly associated with cumulative smoking exposure and the resulting widespread carcinogen-induced genomic damage.

Occupational and environmental carcinogens

Radon, asbestos and other inhaled carcinogens can add risk, usually in the context of tobacco-related susceptibility.

Acquired tumour-suppressor loss

Characteristic acquired genomic disruption of cell-cycle control drives neuroendocrine epithelial transformation rather than a usual inherited cancer syndrome.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Neuroendocrine transformation
A pulmonary neuroendocrine-lineage cell acquires growth and tumour-suppressor abnormalities, producing a highly proliferative malignant clone, which links the underlying lesion to the observed respiratory dysfunction.
2
Rapid central growth
Tumour commonly develops near major bronchi and mediastinal nodes, causing obstruction, collapse and compressive syndromes early.
3
Early dissemination
High proliferation, vascular access and biological aggressiveness lead to lymphatic and blood-borne spread before many patients present.
4
Ectopic hormone production
Neuroendocrine secretion or immune cross-reactivity produces paraneoplastic electrolyte, endocrine and neurological syndromes, thereby altering ventilation, gas transfer or respiratory mechanics.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Central thoracic disease

Cough, haemoptysis, dyspnoea, recurrent collapse, hoarseness and a hilar or mediastinal mass are common because SCLC often begins near major airways and nodes.

Rapid systemic illness

Quickly progressive weight loss, fatigue, liver enlargement, bone pain or declining performance should accelerate tissue and staging rather than trigger repeated empirical infection treatment.

Brain involvement

Headache, vomiting, cognitive or personality change, seizure, ataxia or focal deficit may reflect brain metastases and requires urgent brain imaging and symptom management.

SIADH pattern

Euvolaemic hypotonic hyponatraemia with inappropriately concentrated urine can accompany SCLC, but medications, cortisol deficiency, hypothyroidism and volume disturbance must be excluded.

Lambert-Eaton syndrome

Proximal leg weakness, depressed reflexes that facilitate after effort and autonomic symptoms such as dry mouth can precede cancer diagnosis and warrant neurological plus malignancy assessment.

Compressive emergency

Facial swelling, venous distension, stridor, confusion, spinal pain or weakness may indicate superior vena cava or spinal cord compromise and needs same-day escalation.

Red flags requiring action

Seizure, new focal neurology, altered consciousness or raised-intracranial-pressure features requires urgent brain imaging and acute management before routine outpatient staging.
Airway compromise or neurological symptoms with superior vena cava obstruction needs emergency multidisciplinary care; do not delay stabilisation for an ideal tissue sequence.
Back pain with weakness, sensory level or bladder disturbance suggests metastatic cord compression and must enter the emergency pathway immediately.
Severe symptomatic hyponatraemia can cause seizures or coma; manage the neurological emergency with expert biochemical monitoring while treating the cause.
Fever or haemodynamic deterioration after chemotherapy is neutropenic sepsis until assessed and needs immediate local protocol treatment.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Contrast-enhanced CT chest and upper abdomenFirst step
Why
Define primary, nodal, hepatic, adrenal and other accessible disease before sampling.
Interpretation and limitations
Choose a high-yield low-risk target that confirms diagnosis and maximal stage; bulky central disease may be safer through bronchoscopy or EBUS than percutaneous lung biopsy.
02
Histology or cytology with immunophenotype
Why
Confirm high-grade small-cell neuroendocrine carcinoma and exclude mimics.
Interpretation and limitations
Correlate small-cell morphology with an appropriate immunohistochemical panel and clinical imaging; crushed or scant tissue may require repeat sampling when classification remains uncertain.
03
Brain MRI or contrast CT
Why
Detect intracranial metastases at baseline or when neurological symptoms develop.
Interpretation and limitations
MRI is more sensitive when feasible; findings change limited versus extensive planning and the choice between treatment of known metastases and preventive strategies.
04
FDG PET-CT
Why
Resolve extracranial stage when radical thoracic treatment is being considered.
Interpretation and limitations
Use it to refine the radiotherapy field and identify occult distant disease, confirming an isolated intent-changing lesion where feasible because inflammatory uptake can mislead.
05
Serum and urine osmolality with urinary sodium
Why
Characterise hyponatraemia and assess for SIADH.
Interpretation and limitations
First confirm hypotonicity and clinical volume state, then exclude adrenal, thyroid, renal and medication-related causes before attributing the pattern to ectopic hormone secretion.
06
Baseline treatment fitness
Why
Assess ability to tolerate systemic therapy and thoracic radiotherapy.
Interpretation and limitations
Document performance, blood count, renal and hepatic function, hearing or neuropathy risk, nutrition and comorbidity; repeat after reversible acute illness rather than fixing the decision once.
07
Response CT and brain reassessment
Why
Measure early treatment response and inform consolidation or relapse planning.
Interpretation and limitations
Separate tumour response from infection, atelectasis or treatment change and reassess new neurological symptoms immediately rather than waiting for routine surveillance.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Non-small-cell lung cancer

Morphology, immunophenotype and molecular pathology distinguish NSCLC, which has different staging detail and local or targeted treatment options.

Pulmonary carcinoid

A better-differentiated neuroendocrine tumour usually has a slower tempo and different histological proliferation features, so the complete clinical pattern must be compared before attributing symptoms.

Lymphoma

Bulky central nodes and systemic symptoms can mimic small-cell disease; tissue lineage markers prevent incorrect therapy.

Metastatic neuroendocrine carcinoma

A primary outside lung may share morphology, requiring clinical and imaging correlation to establish origin, and the distinction changes the subsequent clinical pathway.

Granulomatous infection

Tuberculosis or fungal infection can cause central masses and nodes, especially when constitutional symptoms dominate; microbiology and tissue discriminate.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01DIAGNOSEBuild a fast definitive pathwayFirst stepDefinitiveImaging or clinical tempo suggests central high-grade lung cancer compatible with SCLC.

1Identify immediate airway, neurological, metabolic and venous-obstruction emergencies, treating these in parallel with diagnostic planning and early acute-oncology contact.
2DefinitiveUse contrast CT to select one safe high-yield biopsy route, often bronchoscopic or EBUS for central disease, and alert pathology that rapid definitive classification is needed.
3Complete brain imaging and decision-changing extracranial staging without duplicating tests, using PET-CT when a radical limited-stage field remains plausible.
4Bring pathology, TNM, practical limited or extensive category, performance and patient preference to thoracic MDT promptly and agree a documented treatment start plan.

02LIMITEDCoordinate curative-intent therapyConfirmed disease can be treated within a tolerable radical thoracic field and the person is fit for combined treatment.

1Confirm brain and mediastinal staging, radiotherapy volume, organ function and performance, correcting infection, nutrition or electrolyte problems without avoidable delay.
2Offer a specialist platinum-etoposide regimen and plan early concurrent thoracic radiotherapy when tolerable, with sequential therapy considered when concurrence is unsafe.
3Monitor oesophagitis, marrow suppression, renal function, hydration, hearing, neuropathy and pulmonary effects while supporting nutrition and smoking cessation.
4After response, discuss cranial management and surveillance using current NICE guidance, brain imaging, cognitive risks and the person's informed priorities.

03EXTENSIVETreat extensive-stage diseaseDisease extends beyond a safe limited-stage radiotherapy field or has confirmed distant metastasis.

1Assess symptoms, performance, organ function, brain disease and emergency local-treatment needs, and explain that systemic treatment is disease-controlling rather than curative.
2For eligible untreated disease, use atezolizumab with carboplatin and etoposide according to NICE TA638 and the licensed protocol; select another platinum pathway when criteria differ.
3Use radiotherapy selectively for symptomatic brain, bone, airway or thoracic disease and integrate analgesia, antiemesis, nutrition and specialist palliative support early.
4Review clinical and imaging response, continuing maintenance immunotherapy only while indicated and tolerated, with active surveillance for delayed immune toxicity.

04RELAPSEReassess rather than repeat automaticallySymptoms or surveillance imaging show disease recurrence after an initial response.

1Confirm relapse pattern and urgency, including brain imaging for neurological symptoms, while distinguishing infection and treatment toxicity from progressive cancer.
2Review the interval since prior platinum response, residual toxicity, performance, organ function and what the person values before proposing another systemic line.
3AlternativeConsider platinum rechallenge, an alternative licensed therapy, clinical trial or site-directed radiotherapy according to current NICE and oncology guidance rather than a fixed sequence.
4When likely benefit is low or treatment burden conflicts with goals, intensify symptom control, psychosocial support and advance planning without presenting this as no treatment.

05HYPONATRAEMIAManage suspected SIADH safelyA patient with SCLC develops hypotonic hyponatraemia with neurological or systemic symptoms.

1Assess ABCDE, neurological severity, volume state, medication exposure and the speed of sodium change, seeking urgent endocrine or acute medical input for severe symptoms.
2Confirm serum and urine biochemistry and exclude adrenal insufficiency, hypothyroidism, renal failure, diuretics and other contributors before finalising SIADH.
3Use severity-appropriate monitored correction under the local protocol, avoiding both untreated cerebral oedema and overly rapid correction that risks osmotic injury.
4Treat the underlying SCLC when feasible and continue serial biochemical review because recurrence, fluid intake and anticancer therapy can change sodium handling.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Forms the systemic backbone for limited-stage and extensive-stage SCLC, combined with thoracic radiotherapy or immunotherapy where indicated.

Platinum plus etoposide

Intravenous combination cycles prescribed by oncology protocol with organ-function adjustment and supportive medicines.

Myelosuppression, sepsis, nausea, renal effects, electrolyte disturbance, neuropathy and hearing toxicity require regimen-specific monitoring; cisplatin and carboplatin are not interchangeable by simple dose substitution.

Checkpoint inhibitor added to carboplatin and etoposide for eligible untreated extensive-stage SCLC under NICE TA638.

Atezolizumab

Intravenous specialist schedule with induction combination then maintenance according to the licensed pathway.

Immune toxicities may be delayed and involve any organ; active autoimmune disease, transplant, infection, corticosteroid requirement and treatment-related pneumonitis need specialist consideration.

Prevents acute and delayed nausea, protects hydration and supports completion of time-sensitive systemic therapy.

Supportive antiemetic regimen

Risk-adapted prophylaxis before chemotherapy with take-home rescue treatment under local protocol.

Check QT risk, constipation, sedation, interactions, glucose effects and whether symptoms could instead reflect hyponatraemia, brain metastasis or bowel pathology.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Superior vena cava obstruction

Central tumour or nodes compress the vena cava, causing facial and upper-limb swelling, venous distension and occasionally airway or cerebral compromise.

Brain and other metastases

Early haematogenous spread commonly affects brain, liver, bone and adrenal glands, causing organ-specific emergencies, and increasing the burden of otherwise local respiratory disease.

Paraneoplastic syndromes

Inappropriate antidiuretic hormone, ectopic corticotrophin and immune neurological syndromes can cause severe metabolic or functional deterioration.

Airway obstruction

Central endobronchial growth causes lobar collapse, post-obstructive pneumonia, haemoptysis and respiratory failure, and increasing the burden of otherwise local respiratory disease.

Rapid relapse

Initial treatment sensitivity may be followed by resistant recurrent disease because of tumour heterogeneity and early systemic spread.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Before each systemic cycle, review performance, weight, full blood count, renal and hepatic function, electrolytes, infection, hearing or neuropathy and current neurological symptoms.
During combined thoracic treatment, monitor swallowing, nutrition, hydration, pain, cough, marrow suppression and respiratory deterioration, distinguishing oesophagitis and pneumonitis from infection.
For atezolizumab, ask about pulmonary, bowel, hepatic, endocrine, renal, cardiac, skin and neurological symptoms at every contact and after treatment has ended.
Reimage early enough to document response and plan the next phase, but investigate new neurological or compressive symptoms immediately rather than waiting for the scheduled scan.
When SIADH is present, trend sodium and fluid status according to severity and treatment, recording the agreed correction plan to prevent uncoordinated rapid change.
At relapse, document the prior response interval, residual toxicities and current goals because these are more informative than simply recording previous chemotherapy received.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Limited is a treatment concept

The practical limited-stage label asks whether known thoracic disease fits a tolerable radical field; TNM remains important for precise prognosis and communication.

Speed needs coordination

Fast treatment should come from parallel staging, pathology and fitness work, not from skipping tissue or giving an unplanned regimen that creates later uncertainty.

A dramatic response is not cure

SCLC often shrinks rapidly with first-line therapy, but relapse risk remains high. Response should trigger planned consolidation and surveillance rather than false reassurance.

Hyponatraemia has alternatives

Even with SCLC, diuretics, adrenal insufficiency, hypothyroidism, low intake and volume depletion remain possible; correct classification prevents harmful fluid advice.

Brain strategy is individualised

Known brain metastases require treatment, whereas preventive cranial irradiation after response is a separate decision balancing disease risk, imaging, cognition and current guidance.

Relapse interval matters

A durable initial response predicts a different chance of benefit from platinum rechallenge than rapid refractory progression, but fitness and patient preference remain decisive.

11Common pitfallsFrequent interpretation and management errors.

01
Letting sequential referrals delay tissue and staging in a cancer whose clinical tempo demands parallel multidisciplinary coordination.
02
Using limited versus extensive labels without recording TNM anatomy, brain findings and whether a tolerable radical field is actually feasible.
03
Starting thoracic radiotherapy without coordinated systemic timing, target definition and toxicity assessment in a potentially curable patient.
04
Assuming every hyponatraemic patient with SCLC has SIADH without confirming hypotonicity, volume state and endocrine alternatives.
05
Over-correcting severe hyponatraemia through multiple uncoordinated interventions without a documented biochemical monitoring plan.
06
Missing delayed immune toxicity during maintenance atezolizumab or after it stops because symptoms are attributed automatically to progression.
07
Offering the same relapse regimen regardless of prior response interval, organ function, residual toxicity and goals of care.